Blood advances
Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials.
Soon Jye Kho, Sheila S Diamond, Penelope Lafeuille, Jonathan H Schatz, Francesco Maura, Jacob Aptekar, Frederick L Locke
Published: 202510.1182/bloodadvances.2025016361
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has advanced treatment for B-cell lymphoma (BCL), but more than 50% of patients relapse. Predicting clinical outcomes based on features at CAR T infusion remains unclear, and most trials lack racial dive…
Preview only. Read the full abstract at the source